产品名称 SHP099
产品货号 Axon 2633 CAS [1801747-42-1] MF C16H19Cl2N5MW 352.26 Purity: 99% Soluble in DMSO Description Highly potent, selective and orally bioavailable SHP2 inhibitor (IC50 value 0.071 μM) that stabilizes SHP2 in an auto-inhibited conformation. SHP099 potently inhibits ERK phosphorylation and the growth of cancer cell lines that have alterations in RTKs or other tyrosine kinases such as the Janus kinases JAK1 and JAK2. SHP099 showed no detectable activity against a panel of 21 phosphatases and 66 kinases (including the closest homologue SHP1), and only had modest activity against 5HT3 when profiled against a preclinical safety pharmacology panel representing 49 common adverse drug reaction targets. KEYWORDS: SHP099 | supplier | SHP2 inhibitor | SHP-099 | SHP 099 | CAS [1801747-42-1] | [1801747-11-4] | Tyrosine Phosphatase | PTP | PTPN11 | PTP-2C | programmed cell death pathway | PD-1/PD-L1 | Noonan | Leopard | RAS-ERK signaling
产品价格 现货询价,电话:010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

SHP099

Based on 2 reference(s) in Google Scholar 10 10 2

Axon 2633

CAS [1801747-42-1]

MF C16H19Cl2N5
MW 352.26

  • Purity: 99%
  • Soluble in DMSO

SHP099

Description

Highly potent, selective and orally bioavailable SHP2 inhibitor (IC50 value 0.071 μM) that stabilizes SHP2 in an auto-inhibited conformation. SHP099 potently inhibits ERK phosphorylation and the growth of cancer cell lines that have alterations in RTKs or other tyrosine kinases such as the Janus kinases JAK1 and JAK2. SHP099 showed no detectable activity against a panel of 21 phosphatases and 66 kinases (including the closest homologue SHP1), and only had modest activity against 5HT3 when profiled against a preclinical safety pharmacology panel representing 49 common adverse drug reaction targets.

KEYWORDS: SHP099 | supplier | SHP2 inhibitor | SHP-099 | SHP 099 | CAS [1801747-42-1] | [1801747-11-4] | Tyrosine Phosphatase | PTP | PTPN11 | PTP-2C | programmed cell death pathway | PD-1/PD-L1 | Noonan | Leopard | RAS-ERK signaling

产品资料